UPDATE: Goldman Sachs Initiates Rhythm Pharmaceuticals With Sell, $18 Target As Firm Cites 3 Initial Concerns

'We have initial concerns around: (1) the overall strength of the P3 data (e.g., small data sets, variable efficacy); (2) potential for slow market adoption (small patient numbers, low diagnosis rates, launch

Benzinga · 01/08/2020 18:31

'We have initial concerns around: (1) the overall strength of the P3 data (e.g., small data sets, variable efficacy); (2) potential for slow market adoption (small patient numbers, low diagnosis rates, launch execution risk); and (3) commercial challenges previously seen with approved obesity drugs. Further, with our sales and EPS estimates'